Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative.
Joshua D Grill, Lijie Di, Po H Lu...
https://pubmed.ncbi.nlm.nih.gov/22503160/Actively Recruiting
Led by Helse Stavanger HF · Updated on 2026-05-04
200
Participants Needed
6
Research Sites
N/A
Total Duration
Researchers are evaluating fasudil, a ROCK-inhibitor, in people with early Alzheimers disease AD to see if it improves working memory compared to placebo over 12 months. This Phase 2, placebo-controlled, double-blind trial aims to assess the effects of fasudil on cognitive functions, brain metabolism using FDG-PET scans, and other clinical functions and biomarkers in individuals with early AD. Fasudil has shown neuroprotective effects in animal models and is approved in some countries for other uses. The study involves two groups one receiving fasudil and the other receiving a matching placebo. Participants start with a 2-week titration period at 60 mg daily, then increase to a maintenance dose of 120 mg daily for up to 50 weeks. Visits for safety and efficacy evaluations occur every two weeks for the first month and monthly thereafter. The trial enrolls up to 200 people in three cohorts of increasing size, with random assignment to fasudil or placebo. Participants attend regular clinic visits for cognitive testing, FDG-PET scans, and biomarker collection including blood and cerebrospinal fluid samples. Safety is monitored through monthly assessments of vital signs, lab tests, ECGs, and suicide risk scales. The main outcomes include changes in working memory scores and brain metabolism after 12 months. The trial includes ongoing safety review by a Data and Safety Monitoring Board and lasts about one year per participant.
CONDITIONS
Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)
D
Dag Aarsland, PhD
N
Nicolas Castellanos Perilla, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Helse Stavanger HF
Lead Sponsor
University of Exeter
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 months
Participants receive fasudil or placebo, starting with a 2-week titration period at 60 mg daily, then escalating to a 120 mg daily maintenance dose for up to 50 additional weeks.
Visits every 2 weeks for the first month, then monthly visits thereafter
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Joshua D Grill, Lijie Di, Po H Lu...
https://pubmed.ncbi.nlm.nih.gov/22503160/S C Smith, D L Lamping, S Banerjee...
https://pubmed.ncbi.nlm.nih.gov/17176501/F Fazekas, J B Chawluk, A Alavi...
https://pubmed.ncbi.nlm.nih.gov/3496763/J Huntley, A Corbett, K Wesnes...
https://pubmed.ncbi.nlm.nih.gov/28960500/K Herholz, E Salmon, D Perani...
https://pubmed.ncbi.nlm.nih.gov/12482085/Keisuke Ido, Ryota Kurogi, Ai Kurogi...
https://pubmed.ncbi.nlm.nih.gov/32271814/S Kamei, M Oishi, T Takasu
https://pubmed.ncbi.nlm.nih.gov/8889286/Katherine J Sellers, Christina Elliott, Joshua Jackson...
https://pubmed.ncbi.nlm.nih.gov/29055813/Yun Song, Xu Chen, Li-Yan Wang...
https://pubmed.ncbi.nlm.nih.gov/23638992/Clive Ballard, Dag Aarsland, Jeffrey Cummings...
https://pubmed.ncbi.nlm.nih.gov/32939050/Helse Stavanger HF
Lead Sponsor
University of Exeter
Collaborating Sponsor